Results from the Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (DAPA-HF) showed that dapagliflozin, an SGLT2 inhibitor, reduced the incidence of type 2 diabetes by 32% in patients with heart failure but without diabetes at baseline. “While the major role of dapagliflozin is to reduce cardiovascular mortality and worsening of heart failure, decreasing incident diabetes could be considered an additional benefit,” said Silvio E. Inzucchi, MD.
ICYMI: Dapagliflozin slows onset of type 2 diabetes in patients with heart failure, study finds
